# Evaluation of Efficacy and Safety of Combination Therapy of Henagliflozin Proline, Retagliptin and Metformin in New Diagnosed Type 2 Diabetes Patients

> **NCT06417489** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Peking University First Hospital** · enrollment: 160 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Combination therapy
- **DRUG:** Sequential treatment group

## Key facts

- **NCT ID:** NCT06417489
- **Lead sponsor:** Peking University First Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05-31
- **Primary completion:** 2026-05-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06417489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06417489, "Evaluation of Efficacy and Safety of Combination Therapy of Henagliflozin Proline, Retagliptin and Metformin in New Diagnosed Type 2 Diabetes Patients". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06417489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*